Teaser:This review presents an overview of the immune-related hurdles that limit mRNA advance for non-immunotherapy related applications and suggest some promising methods to reduce this 'unwanted' innate immune response.
Author photographs and biographiesJoke Devoldere (1990) Her project lies on the interface between material science and immunology as it aims to develop novel micro-and nanomaterials for the delivery of antigen-coding mRNA to induce antitumor immunity. With her research, she won several awards, among which the "Therapeutic use of microbubbles" oral presentation award (Rotterdam, The Netherlands) and the Jan Feijen poster prize at the 13 th European symposium on controlled drug delivery (Egmond aan Zee, The Netherlands). Evading innate immunity in non-viral mRNA delivery: don't shoot the messenger
AbstractIn de field of non-viral gene therapy, in vitro transcribed (IVT) mRNA has emerged as a promising tool for the delivery of genetic information. Over the past few years it has become widely known the introduction of IVT mRNA into mammalian cells elicits an innate immune response which has favored mRNA use towards immunotherapeutic vaccination strategies. However, for non-immunotherapy related applications this intrinsic immune-stimulatory activity directly interferes with the aimed therapeutic outcome, as it can seriously compromise the expression of the desired protein. This review presents an overview of the immune-related obstacles that limit mRNA advance for non-immunotherapy related applications.